- New York Dermatology 30 East 60th Street (Park/Madison) 8th Floor Suite 805 New York, NY
- HPV Vaccine Monitoring Human Papillomavirus (HPV) Vaccine Post-Licensure Monitoring and
- Implementation Activities (Updated June 2011)
- 212.644.6454
- Two HPV vaccines are licensed for use in females in the US
- the quadrivalent HPV vaccine (Gardasil), which protects against HPV types 6, 11, 16 and 18
- bivalent HPV vaccine (Cervarix) which protects against types 16 and 18)
- High risk, or oncogenic types, including types 16 and 18, can cause high-grade cervical cell abnormalities that are precursors to cervical cancer and other cancers such as vulvar, vaginal and anal cancers as well as some oropharyngeal cancers
- In the U.S., post-licensure vaccine monitoring routinely includes determination of vaccine coverage, monitoring for disease impact, vaccine safety and vaccine implementation
- Human Papillomavirus (HPV) Vaccine Post-Licensure Monitoring and Implementation Activities outlines established efforts for post-licensure monitoring; to which HPV has been added, as well as new efforts and activities at CDC.
- Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, with approximately 20 million people currently infected and an estimated 6.2 million additional people who become newly infected every year
|
|
